Posted by Michael Wonder on 04 Nov 2021
Libtayo (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small-cell lung cancer expressing PD-L1 in ≥ 50% of tumour cells with no EGFR, ALK or ROS1 aberrations
29 October 2021 - The approval is based on data from the randomised, open-label, multi-center study 16241.
Libtayo (cemiplimab) is now approved in Canada for the first-line treatment of adult patients with non-small-cell lung cancer expressing PD-L1 in ≥ 50% of tumour cells (tumour proportion score ≥ 50%), as determined by a validated test with no EGFR, ALK, or ROS1 aberrations, who have locally advanced non-small-cell lung cancer who are not candidates for surgical resection or definitive chemoradiation or metastatic non-small-cell lung cancer.
